Catálogo de publicaciones - libros

Palabras clave – provistas por la editorial

acute lymphoblastic leukemia; pediatric; advances; diagnosis; treatment; immunotherapy; bispecific T-cell engager (BiTE); BCP-ALL; leukemia; TRAIL; antibody; Fc-engineering; xenograft; CD19; juvenile myelomonocytic leukemia; RAS signaling; hematopoietic stem cell transplantation; 5-azacitidine; myelodysplastic/myeloproliferative disorders; targeted therapy; ADC; antibody–drug conjugate; pediatric leukemia; ALL; AML; allogeneic stem cell transplantation; acute myeloid leukemia; minimal residual disease; conditioning regimen; alternative donors; B-ALL; DUX4; IKZF1; PAX5; Ph-like; ZNF384; NUTM1; T-ALL; NOTCH1; BCL11B; transcriptome; genome; chronic myeloid leukemia; CML; tyrosine kinase inhibitor; immunizations; COVID-19; childhood acute lymphoblastic leukemia; low-risk ALL; risk-stratified treatment; treatment related toxicity; L-asparaginase; acute pancreatitis; polymorphism; SNV; ABCC4; CFTR; other extramedullary relapse; lymphoblastic leukemia; children; prognosis; evolution of CAR T cells; FDA-approved CAR products; TcR versus CAR; limitations and complications of CAR T cell therapy; future directions of CAR T cell therapy; n/a